Levocetirizine Research Articles

STABILITY INDICATING RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS QUANTIFICATION OF ANTIHISTAMINIC & ASTHMATIC DRUG IN BULK AND TABLET DOSAGE FORM

This research describes the stability indicating RP-HPLC method in pharmaceutical tablet dosage forms for simultaneous estimation of Levocetirizine dihydrochloride (LEV) and Montelukast Sodium (MON). The proposed RP-HPLC method was developed using separation module Waters 2695 with PDA detector and chromatographic separation was performed at a flow rate of 1 mL / min using column Hypersil BDS C18 (250/4.6 mm, 5 μm) with a run time of 10 min. The mobile phase consisted of a 40:60% v / v Phosphate buffer and acetonitrile, pH with orthophosphoric acid was adjusted to 7.0 and the eluents were scanned at 230 nm using a PDA detector. Retention times for LEV and MON were 3.06 min, and 6.76 min, respectively. A linearity response was observed with a concentration range of 12.56–37.68 μg / mL for LEV and 23.78–71.20 μg / mL for MON. Limit of detection and limit of quantification for LEV are 0.079 µg/mL and 0.239 µg/mL and for MON are 0.156 µg/mL and 0.473 µg/mL, respectively. The stability indicating method was developed by subjecting the drugs to stress conditions such as acid, base hydrolysis, oxidation, neutral, photo- and thermal degradation, and the degraded products produced from the samples were successfully solved.

Palatable Levocetirizine Dihydrochloride Solid Dispersed Fast-Dissolving Films: Formulation and In Vitro and In Vivo Characterization.

One of the most important issues for bitter-tasting drugs such as levocetirizine dihydrochloride (LCD) is the production of palatable dosage forms. LCD also has a delayed onset of action following oral administration. In this study, solid dispersed fast-dissolving films (FDFs) of LCD using the solvent casting method for oral application were prepared and evaluated. The FDF is composed of HPMC as the film forming polymer and different types of superdisintegrants (sodium starch glycolate, croscarmellose sodium, or crospovidone). FDF containing crospovidone showed the highest percentage release of the drug (100.54% ± 1.47 within 3 min.) and was chosen for fabricating into palatable solid dispersed FDFs using different ratios of gelatine. The results of Raman and FTIR revealed that the drug's crystalline structure has been disrupted, and the drug has intermolecular hydrogen bonds with gelatine. The solid dispersed FDF (LF-7), which contained the drug in the form of a 1 : 1 solid dispersion with gelatine, showed a rapid in vitro disintegration (25 seconds) and a burst release of the drug (99.22% ± 2.22 within one min). The in vivo studies were conducted on human participants and showed a significant (p < 0.05) reduction in disintegration time (9.43 ± 2.16 sec.) and higher taste masking ability of the solid dispersed FDF (LF-7) compared to the nonsolid dispersed FDF (LF-4). The stability studies indicated that the prepared FDF remained stable over three months. Overall, FDFs of levocetirizine dihydrochloride with a palatable and rapid onset of action were developed to relieve allergic symptoms.

Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis.

In prior clinical studies, levocetirizine (LEVO) has demonstrated no effect on ventricular repolarization (QTc intervals), therefore it is a relevant negative control to assess in nonclinical assays to define low proarrhythmic risk. LEVO was tested in beagle dog and cynomolgus monkey (nonhuman primate [NHP]) telemetry models to understand the nonclinical-clinical translation of this negative control. One oral dose of vehicle, LEVO (10mg/kg/species) or moxifloxacin (MOXI; 30 mg/kg/dog; 80 mg/kg/NHP) was administered to instrumented animals (N=8/species) using a cross-over dosing design; MOXI was the in-study positive control. Corrected QT interval values (QTcI) were calculated using an individual animal correction factor. Blood samples were taken for drug exposure during telemetry and for pharmacokinetic (PK) analysis (same animals; different day) for exposure-response (C-QTc) modeling. Statistical analysis of QTc-by-timepoint data showed that LEVO treatment was consistent with vehicle, thus no effect on ventricular repolarization was observed over 24 h in both species. PK analysis indicated that LEVO-maximum concentration levels in dogs (range: 12,300-20,100 ng/ml) and NHPs (range: 4090-12,700 ng/ml) were ≥4-fold higher than supratherapeutic drug levels in clinical QTc studies. Slope analysis values in dogs (0.00019 ms/ng/ml) and NHPs (0.00016 ms/ng/ml) were similar to the human C-QTc relationship and indicated no relationship between QTc intervals and plasma levels of LEVO. MOXI treatment caused QTc interval prolongation (dog: 18 ms; NHP: 29 ms). The characterization of LEVO in these non-rodent telemetry studies further demonstrates the value and impact of the in vivo QTc assay to define a "no QTc effect" profile and support clinical safety assessment.

Topical Formulation of Nano Spray-Dried Levocetirizine Dihydrochloride against Allergic Edema.

Levocetirizine dihydrochloride active ingredient was microencapsulated using nano spray-drying technology for preparing microparticles containing topical gel against edema. Hydroxyl propyl methyl cellulose (HPMC) was used as a carrier polymer during spray drying. The active ingredient content of the nano spray-dried products was 52.81% (w/w) and 51.33% (w/w) for ex vivo and in vivo experiments, respectively, and the average particle size was 2.6 µm. X-ray diffraction analysis indicated an amorphous state of the active ingredient embedded in the amorphous matrix of the polymer. Dermal oil gels composed of Miglyol 812 gelated by Dermofeel viscolid included 5% (w/w) (for ex vivo) and 10% (w/w) (for in vivo) active ingredient without or with 0.05% (w/w) menthol penetration enhancer. Qualitative ex vivo penetration studies using a confocal Raman microscopic correlation mapping were executed on human abdominal skin. The results showed that the active ingredient was enriched in the epidermis and upper dermis layer of the skin using oleogel loaded with the nano spray-dried drug-HPMC composite. Menthol addition to the oleogel resulted in the concentration of levocetirizine in the dermis. In vivo tests were performed on a mouse model of croton oil-induced ear edema. Negative control and Fenistil-treated groups were compared using the prepared oil gels with and without menthol. Without penetration enhancer, 20 µL of our oil gel loaded with nano spray-dried levocetirizine dihydrochloride composite showed similar effectiveness to the same volume of Fenistil gel, while 5 µL menthol containing sample was sufficient to eliminate the skin irritation similarly to 20 µL Fenistil.

Significance of modern antihistamines in the treatment of patients with allergic rhinitis

Allergic rhinitis (AR) is one of the most common diseases in the world, which is based on immunoglobulin E (IgE) – mediated inflammation that develops after contact with various allergens. About 40 % of people suffer from various allergic diseases, every 3 rd inhabitant of the Earth has symptoms of allergic rhinitis and every 10 th has bronchial asthma. The early phase of allergen binding to IgE antibodies occurs within a few minutes after contact, the late phase develops after 4–6 hours. In addition to the airborne pathway of penetration, contact with the allergen is possible through the skin and mucous membranes, gastrointestinal tract, with parenteral administration of drugs. Taking into account the etiotropic factor, there are year-round allergic rhinitis (CAR) and seasonal (SAR). By the nature of the course, intermittent and persistent allergic rhinitis are distinguished. The most basic symptoms of allergic rhinitis include: sneezing, rhinorrhea, nasal congestion, itching, decreased sense of smell. Treatment includes antihistamines, intranasal steroids, leukotriene receptor antagonists and immunotherapy. To date, antihistamines of the second generation are recommended and widely used for the treatment of patients with allergic rhinitis, the main representative of which is levocetirizine (levocetirizine dihydrochloride). The purpose of the work is an analytical review of the results of clinical trials of levocetirizine for allergic rhinitis. The article discusses in detail the prevalence, etiology and pathogenesis, classification of the disease, treatment regimens for patients with allergic rhinitis, and provides two own clinical observations. Based on the data of a number of studies, the advantages of using antihistamines of the second generation in allergic rhinitis have been demonstrated, expanding not only the possibilities of treating patients, but also preventing the transition of the disease into a chronic process.

Formulation Optimization and Evaluation of Taste Masked Oro-dispersible Tablet of Levocetrizine Dihydrochloride by Ion Exchange Resin

The aim of this study was to prepare ODT of taste masked levocetrizine dihydrochloride by using ion exchange resin. Levocetrizine Dihydrochloride is bitter in taste, Kyron T-134 a weak cationic exchange resin was used to mask the bitter taste of the drug. The ODTs were prepared by using drug-resin (DRC) complex using batch process. Compression of ODTs was done by using direct compression method with the technique of addition of superdisintegrants. Central composite design (CCD) was applied as an optimization technique. FTIR and DSC studies indicated drug and excipients were compatible with each other. The prepared orodispersible tablet blend and tablets were evaluated for various pre-compression and post-compression parameters. The Batch LH3 was given as optimized batch by central composite design. This optimized batch LH3 was passed all the pre-compression and post- compression parameters. The prepared ODTS showed successfully rapid onset of action with decrease in disintegration time 26 sec and %drug released was found to be 98.26%. It was concluded that levocetrizine dihydrochloride ODTs were prepared successfully by taste masking method using Kyron T-134 ion exchange resin and croscarmellose sodium as Superdisintegrant using CCD. AS per CDER guidelines, it shows DT within 5-30 sec.

Green potentiometric determination of some of the third-generation antihistamines: Fexofenadine, Desloratadine, and Levocetirizine by using new carbon paste electrodes

BackgroundThe Current study describes the construction of three carbon paste electrodes for the quantitative measurement of the third-generation antihistamines fexofenadine (FEX), Desloratadine (DES), and Levocetirizine (LEV). The different assembly steps of the sensor are described. The proposed potentiometric method Presents a green, fast, simple, and sensitive procedure for the determination of these drugs in their pure and pharmaceutical forms. ResultsThe quantitative determination of the antihistamines drugs was achieved using the constructed carbon paste electrodes. The presented analytical method obeyed linearity in the concentration range (5 × 10−6–1 × 10−2) M for FEX and DES, (1 × 10−5 – 1 × 10−2) M for LEV. The values of the Nernstian slopes (-57.40, -29.01, -56.01) mV/ decade indicate the closeness of these values from the ideal Nernstian slope value. The limits of quantification (LOQ) were (2.17 × 10−8- 6.31 × 10−8- 3.3 × 10−8) M, respectively. In addition, the electrodes exhibited good selectivity, repeatability (RSD<2%), stability, and fast response time. The method was validated and employed for the determination of the studied drugs in pharmaceutical dosage forms, the average recovery values were (99.13–99.53–99.90)% for FEX, DES, and LEV, respectively. ConclusionOur study included the construction of the first carbon paste electrodes for potentiometric determination of some of the third-generation antihistamines. The findings have shown that carbon paste electrodes excel over the traditional ion -selective electrodes and present an accurate, precise, green, robust, and cost-effective analytical method.

Dual Delivery of Fluticasone Propionate and Levocetirizine Dihydrochloride for the Management of Atopic Dermatitis Using a Microemulsion-Based Topical Gel.

The current study investigates the potential for topical delivery of a fluticasone propionate (FP) and levocetirizine dihydrochloride (CTZ)-loaded microemulsion (ME) for the management of atopic dermatitis. Various microemulsion components were chosen based on their solubility and emulsification capabilities, and the ternary phase diagram was constructed. A total of 12 microemulsion formulations were screened for various attributes like vesicle size, polydispersity index, ζ-potential, percent transmittance, density, and pH. The average globule size and ζ-potential of FP and levocetirizine-containing ME were 52.12 nm and −2.98 ζ-potential, respectively. Transmission electron microscopy confirmed the spherical nature of the globules. The developed system not only controlled the release of both drugs but also enhanced the efficacy of the drugs on a rodent model. Histopathological studies confirmed the safety of the developed system. The present findings provide evidence for a scalable and simpler approach for the management of atopic dermatitis.

Volumetric and Conductivity Studies of the Interaction between Levocetirizine Dihydrochloride and the Amino Acids L-Alanine and L-Glutamine in Aqueous Solutions

Volumetric and Conductivity Studies of the Interaction between Levocetirizine Dihydrochloride and the Amino Acids L-Alanine and L-Glutamine in Aqueous Solutions

Therapeutic effects of Probiotic Ointment for Atopic Dermatitis

The human microbiome is an integral part of the body, playing a crucial role in metabolism, energy homeostasis, the regulation of the immune system, and others. The study aims to examine the effect of probiotic ointment on the qualitative composition of the lesional skin microbiome in patients with atopic dermatitis. The study population consisted of 110 patients aged 20 to 45 years with mild atopic dermatitis (AD). The patients were divided into two groups. One group received four different medications: levocetirizine dihydrochloride, enterosgel, topical Tizol gel, and topical 1% hydrocortisone ointment. The other group received a similar treatment with four different medications: levocetirizine dihydrochloride, enterosgel, topical Tizol gel, and topical probiotic ointment. The treatment period was one month. After treatment, the frequency and intensity of the main AD symptoms significantly decreased. A load of S. aureus fell in the probiotic-treated group from 73.4% to 29.1% (p&lt;.05). In the standard-treated group, the S. aureus load decreased from 78.2% to 43.6% (p&lt;.05). The study found that the standard treatment without probiotics helped to decrease S. aureus colonisation in AD patients by 2.00 times (p&lt;.05), whereas using the probiotic ointment reduced S. aureus colonisation by 3 times (p&lt;.05).

Study in the solid state, framework energy and crystal structure by X-ray diffraction techniques of cetirizine and levocetirizine dihydrochloride used as antihistamines

Study in the solid state, framework energy and crystal structure by X-ray diffraction techniques of cetirizine and levocetirizine dihydrochloride used as antihistamines

Preparation and Characterization of Chitosan Silicate Conjugate: It’s Role as a Super Disintegrant in Orally Fast Dissolving Films

Abstract: Aim: The aims of the present research work was to prepare and characterize the chitosan silicate conjugate, conjugate was included in orally fast dissolving films of levo cetirizine di hydrochloride as a super disintegrant and to compare disintegration efficiency with commercial super disintegrant. Materials and Methods: Conjugate was prepared by reacting chitosan with colloidal silicon dioxide. Characterized primarily by determining the charring point, viscosity and wicking property confirmed by Fourier transforms infrared spectroscopy, differential scanning calorimetry and X-ray powder diffraction analysis. The compatibility between the drug excipients was confirmed by Fourier transforms infrared spectroscopy and differential scanning calorimetry. Orally fast dissolving films were prepared by solvent casting technique by using hydroxypropyl methylcellulose E15, polyethylene glycol 400 as the plasticizer, conjugate and crospovidone as super disintegrants. The films were subjected to post-formulation parameters by determining weight variation, thickness, swelling index, folding endurance, tensile strength, percentage elongation, drug content, drug content uniformity, in vitro disintegration time, in vitro dissolution study, in vitro permeation study, surface morphology and accelerated stability studies. Results: The results of characterization of prepared conjugate revealed that conjugation took place. Compatibility study suggested that drug and excipients were compatible. The prepared films were having smooth surface, drug was uniformly distributed, had good physical and tensile strength. The film consists of 100 mg of conjugate as super disintegrant took less time for disintegration as compared with 100 mg of commercial super disintegrant. Conclusion: By considering the results of the present study may be concluded that the disintegration capacity of prepared conjugate was high compared to commercial disintegrant. Key words: Orally fast dissolving films, Chitosan silicate conjugate, Super disintegrant, Disintegration time, in vitro dissolution, in vitro permeation, Reversed phase-high performance Liquid chromatography.

Crystal structure of levocetirizine dihydrochloride Form I, C21H27ClN2O3Cl2

The crystal structure of levocetirizine dihydrochloride Form I has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional techniques. Levocetirizine dihydrochloride Form I apparently crystallizes in space group P21/n (#14) with a = 24.1318(21), b = 7.07606(9), c = 13.5205(7) Å, β = 97.9803(4)°, V = 2286.38(12) Å3, and Z = 4. The crystal structure consists of interleaved double columns of cations and anions along the short b-axis. The hydrogen bonds link the cations and anions along this axis. Each protonated nitrogen atom forms a strong N–H⋯Cl hydrogen bond to one of the chloride anions. The carboxylic acid group also forms an H-bond to Cl56, resulting in a ring with a graph set R1,2(10). The centrosymmetric P21/n model for the crystal structure of levocetirizine dihydrochloride is better than the non-centrosymmetric P21 model, even though levocetirizine is a chiral molecule; the sample exhibits weak second-harmonic generation, and three weak peaks which violate the glide plane are observed. The centrosymmetric model is better by statistical, graphical, and energetic measures, as well as by chemical reasonableness. To accommodate the chiral molecule in a centrosymmetric space group, the chiral central carbon atom was disordered over two half-occupied positions, so that each cation site could be occupied by a cation of the correct chirality. A powder pattern from a Le Bail extraction of this synchrotron data set is included in the Powder Diffraction File™ as entry 00-066-1627.

Stability Indicating RP-HPLC method development and validation for simultaneous quantification of antihistaminic &amp; anti-asthmatic drug in bulk and tablet dosage form

Stability Indicating RP-HPLC method development and validation for simultaneous quantification of antihistaminic & anti-asthmatic drug in bulk and tablet dosage form - JPBS- Print ISSN No: - Online ISSN No:- 2320-1924 Article DOI No:- 10.18231/j.jpbs.2020.003, Journal of Pharmaceutical and Biological Sciences-J Pharm B

Forced degradation study of different brands of levocetirizine dihydrochloride by UV-spectroscopy

The goal of this study is to carry out degradation studies of Levocetirizine market-available tablet brands. Forced degradation is the process which involves degradation of the drug products which can be studied to determine the molecule's stability. Various brands of levocetirizine dihydrochloride (Okacet-L, LECOPE, Levocet, 1-AL) were used. It is an H receptor antagonist and is used in the treatment of persistent or seasonal allergic rhinitis and chronic idiopathic urticaria. As per ICH recommendations, this drug has been subject to various stress conditions during the study. In the presence of degradation products, an ultraviolet spectroscopic (UV) method for drug analysis has been developed. The pH 7.0 phosphate buffer was used as solvent. The amount of degraded drug was determined by taking the 230 nm absorbance. All products have been degraded under conditions of acidic, oxidation, photolytic and thermal degradation, and less degraded in alkaline conditions. In all conditions of degradation the tablet of brands Levocet and LECOPE showed less degradation than the brand name tablets Okacet-L and 1-AL.

Cough in patient with concomitant allergic pathology

Cough is among the most common complaints for which patients seek medical attention. This symptom is often caused by pathology of the respiratory system. The need for the treatment of cough as such, that is, prescription of the so-called antitussive drugs, arises mainly in patient with nonproductive, dry, persistent cough. Antitussive drugs are amongst the most widely used medications worldwide. Dextromethorphan is one of the safe and effective over-the-counter cough medicines.In clinical practice, we can often see a combination of an allergic and infectious process in one patient. Against the background of allergies, conditions are created for the accession of a secondary infection or the occurrence of an infectious disease. The second generation antihistamine drug levocetirizine prevents the development and facilitates the course of allergic reactions, and also has decongestant, antipruritic, and antiinflammatory effects.Thus, given the presence of an allergic pathology or a burdened allergic history, clinical symptoms, the nature of the cough (dry, nasal, unproductive, does not help clear the airways, is difficult for patients to tolerate, leads to sleep disturbances), it seems reasonable and advisable to prescribe a combined drug, which contains antitussive and antihistamine components.The drug Cetlo® Plus is presented on the Ukrainian pharmaceutical market, 1 tablet of which contains dextromethorphan hydrobromide 7,5 mg and levocetirizine dihydrochloride 5 mg. The active substances are safe and very well studied, incl. and their interactions with other drugs used in the treatment of concomitant diseases, their clinical effect is predictable. The synergistic therapeutic effect of dextromethorphan and levocetirizine allows for the pathogenetic and symptomatic effects on dry cough in patients with respiratory tract infections and concomitant allergic pathology. A simple regimen for adult patients and adolescents from 12 years old – 1 tablet 1 time per day. The experience of use has proven the effectiveness and good tolerance of the drug, therefore Cetlo® Plus can be recommended for widespread use in clinical practice by a therapist and family doctor.

Formulation and Evaluation of Levocetirizine Dihydrochloride and Ambroxol Hydrochloride Lozenges

The present work aims to formulate and evaluate levocetirizine dihydrochloride and ambroxol hydrochloride hard candy lozenges to produce a slow-release of drugs for the management of cold and cough. The lozenges were prepared using sucrose, liquid glucose, hydroxyethylcellulose, and hydroxypropyl methylcellulose K4M by heating and congealing method. Sweetener with flavors was utilized to facade the bitter taste of the drug. The developed lozenges were exposed to various physical and chemical characters, and in vitro disintegration and dissolution. The developed formulations include hardness of 8 to 11 kg/cm², non-gritty, and agreeable mouthfeel. The optimized formula was examined for drug excipient interactions subjecting to Fourier transform infrared (FTIR) spectral analysis. Drug release for lozenges was highest in formulation FL8. The hard candy lozenges can present an attractive substitute formulation in allergic conditions.

FORMULATION DEVELOPMENT AND CHARACTERIZATION OF EFFERVESCENT TABLETS ALONG WITH LEVOCETIRIZINE DIHYDROCHLORIDE

Objective: Levocetirizine dihydrochloride is also known as “Xyzol.” Levocetirizine dihydrochloride is a second-generation piperazine derivative, potent H1 selective agent. Levocetirizine dihydrochloride is the active R (-) enantiomer of cetirizine dihydrochloride. In the case of an allergic or histaminic reaction, the medication must respond rapidly. Many older patients, infants, and dysphagia patients have trouble swallowing traditional tablets or capsules. Hence, a need exists for a relatively fast-acting effervescent tablet form.&#x0D; Methods: The tablets were prepared by direct compression method using citric acid and sodium bicarbonate as effervescent agents. Then, they were tested for parameters of pre- and post-compression. Tablets were evaluated for studies of general appearance, uniformity of substance, hardness, friability, and in vitro dissolution.&#x0D; Results: More than 90% of the drug was released from almost all the formulations within 1 min. More formulations underwent rapid 90-day stability trials.&#x0D; Conclusion: No major changes in the taste, disintegration, and dissolution profiles were found in tablets.

Sensitive Detection of Levocetirizine as a new Generation Antihistamine by Stripping Square Wave Voltammetry

Background:: new and selective electrochemical sensor was developed for the determination of levocetirizine dihydrochloride, which is an antihistaminic drug. Method:: The investigation was performed by using cyclic, differential pulse and square wave voltammetric methods on the β-cyclodextrin modified glassy carbon electrode. It is thereby planned to obtain information about levocetirizine determination and its mechanism. Result:: The efficiency of experimental parameters including pH, scan rate, and accumulation potential and time on the anodic response of levocetirizine dihydrochloride was studied. By employing the developed method and under optimized conditions, the current showed linear dependence with a concentration in the range between 2 × 10-8 M and 6 × 10-6 M in pH 2.0 Britton Robinson (BR) buffer. Conclusion:: The achieved limits of detection and quantification were found as 3.73 × 10-10 M and 1.24 × 10-9 M, respectively. In addition, the possibility of applying the developed sensor for real sample analysis was investigated, so β-cyclodextrin modified glassy carbon electrode was used to determine levocetirizine dihydrochloride in Xyzal® tablet dosage form. Finally, this sensor was successfully applied to the real sample as a selective, simple, reproducible, repeatable electrochemical sensor.

Development of medicated chewing gum of taste masked levocetirizine dihydrochloride using different gum bases: in vitro and in vivo evaluation

Objective: The aim of this study was to develop medicated chewing gum (MCG) formulation for taste-masked levocetirizine dihydrochloride (LCZ) that can provide fast drug release into the salivary fluid.Methods: Taste-masked LCZ was first prepared by two methods: cyclodextrin complexation using Kleptose or Captisol and formation of drug resin complex using Kyron T-154 or Kyron T-314 to overcome poor LCZ palatability. MCGs were then prepared using the taste-masked drug, gum base (Artica-T, Chicle, or Health In Gum (HIG), plasticizer (glycerol or soy lecithin at 6 or 8% of the final gum weight). The developed MCGs were evaluated for physical properties, content uniformity, and drug release. Best release MCGs were evaluated thermally to investigate the plasticizer effectiveness and for ex vivo chew out study to confirm adequate drug release. Drug bioavailability was determined for selected formula compared to commercial tablets.Results: Based on taste-masking efficiency, drug/Kleptose complex (1:3 molar ratio) was chosen for incorporation into chewing gums. Physical properties and drug release showed that gum base type, plasticizer type, and level affected not only physical properties but also drug release from MCGs. Thermal study showed decreased glass transition temperature (Tg) with increased plasticizer level. Chew out study confirmed almost complete drug release after a few minutes of chewing. Pharmacokinetic results showed shorter tmax (0.585 vs. 1.375 h) and higher Cmax (0.113 vs. 0.0765 μg/mL) for MCGs than conventional tablets.Conclusion: Results provided evidence that MCGs could be a better alternative to conventional tablet formulations with improved bioavailability and enhanced palatability.